抑郁症及抗抑郁药反应的新型外周生物标志物
在小型概念验证研究中,49例重度抑郁症(MDD)患者与59名健康对照的血小板样本显示,MDD组前列腺素E1(PGE1)激活腺苷酸环化酶活性显著低于对照(p=0.02)。19例MDD患者完成6周开放标签抗抑郁治疗,11例应答者PGE1刺激的腺苷酸环化酶较非应答者显著增加(p=0.05),效应量0.83。
要点
- MDD患者血小板Gsα主要位于脂筏,PGE1激活腺苷酸环化酶活性显著低于健康对照(p=0.02)。
- 抗抑郁药应答者PGE1刺激的腺苷酸环化酶较非应答者显著增加(p=0.05),效应量0.83。
- PGE1刺激增加≥30%者中应答者8例(72.7%)、非应答者2例(25.0%),阳性预测值80.0%。
核心结论
- 在这项小型先导研究中,PGE1刺激的腺苷酸环化酶增加与MDD患者的抗抑郁药应答相关。
- 这些数据提示,可开发一种简单、高通量的检测方法用于抑郁症及抗抑郁药应答评估。
- 未来研究需要评估该生物标志物用于MDD治疗的价值。
研究设计与样本
- 小型概念验证研究,筛选访视时纳入49例MDD患者(HamD17评分≥15)和59名健康对照。
- 采用AlphaScreen(PerkinElmer)检测评估Gsα-腺苷酸环化酶的基础活性及前列腺素E1(PGE1)刺激活性。
- 随后19例同意参加的MDD患者完成6周开放标签抗抑郁药治疗试验。
主要发现
- 筛选时,MDD患者血小板样本的PGE1激活腺苷酸环化酶活性显著低于健康对照(p=0.02)。
- 11例抗抑郁药应答者(HamD17较筛选时改善≥50%)的PGE1刺激腺苷酸环化酶较非应答者显著增加(p=0.05),PGE1/Gsα脂筏生物标志物效应量为0.83。
- 8例应答者(72.7%)和2例非应答者(25.0%)的PGE1刺激较筛选时增加≥30%(Fisher精确检验=0.07),阳性预测值为80.0%。
局限性
- 原文称本研究为小型先导研究。
- 原文指出未来研究需要评估该生物标志物用于MDD治疗的价值。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In contrast to healthy controls, the heterotrimeric G protein, Gsalpha (Gsα) is ensconced predominantly in lipid rafts in subjects with major depressive disorder (MDD) resulting in impaired stimulation of adenylyl cyclase. In this small proof-of-concept study, we examined the hypothesis that translocation of Gsα from lipid rafts toward a more facile activation of adenylyl cyclase is a biomarker for clinical response to antidepressants. There were 49 subjects with MDD (HamD17 score ≥15) and 59 healthy controls at the screen visit. The AlphaScreen (PerkinElmer) assay measured both basal activity and prostaglandin E1 (PGE1) stimulation of Gsα-adenylyl cyclase to assess the extent of coupling of Gsα with adenylyl cyclase. At screen, platelet samples obtained from MDD subjects revealed significantly lower PGE1 activation of adenylyl cyclase activity than controls (p = 0.02). Subsequently, 19 consenting MDD subjects completed a 6-week open label antidepressant treatment trial. The 11 antidepressant responders (HamD17 improvement ≥50% from screen) revealed significant increase in PGE1-stimulated adenylyl cyclase compared to non-responders (p = 0.05) with an effect size of 0.83 for the PGE1/Gsα lipid-raft biomarker. PGE1 stimulation increased by ≥30% from screen assessment in eight responders (72.7%) and two non-responders (25.0%) [Fisher exact = 0.07] with a positive predictive value for response of 80.0%. In this small, pilot study, increased PGE1 stimulated adenylyl cyclase was associated with antidepressant response in MDD subjects. These data suggest that a simple, high-throughput-capable assay for depression and antidepressant response can be developed. Future studies are needed to evaluate the utility of this biomarker for the treatment of MDD.
引用
- Targum SD, Schappi J, Koutsouris A, et al. A novel peripheral biomarker for depression and antidepressant response. Mol Psychiatry. 2022. PMID: 34969978. doi:10.1038/s41380-021-01399-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。